XOMA Royalty Corporation Depositary Shs Repr 1/1000th 8.375% Cum Conv Perp Red Pfd Rg Shs Series B XOMAO 深 沪
等待开盘 01-21 09:30:00 美东时间
25.3499
+0.030
+0.12%
华盛通- 最 高25.37
- 今 开25.37
- 成交量 1545股
- 最 低 25.275
- 昨 收 25.32
- 总市值 4055.98万
- 52周最高 25.4268
- 市盈率 静 --
- 换手率 0.10%
- 52周最低 21.7497
- 委 比 57.05%
- 总股本 160.00万
- 历史最高 25.4268
- 量 比 1.54
- 振 幅 0.38%
- 历史最低 14.0698
- 每 手 1
- 风险率 0.67%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多XOMA Royalty Appoints New Chief Financial Officer
Xoma ( ($XOMA) ) has shared an update. XOMA Royalty Corporation announced a lea...
01-16 05:48
XOMA Royalty shares are trading lower after the company announced the resignation of CFO Thomas Burns.
XOMA Royalty shares are trading lower after the company announced the resignati...
01-13 01:51
XOMA Royalty announces CFO transition
XOMA Royalty Corporation (XOMA) announced that chief financial officer Thomas Burns will step down. The company has appointed Jeffrey Trigilio as its new CFO as part of the leadership transition. Trig...
01-12 20:44
XOMA Royalty Announces CFO Transition
XOMA Royalty Corporation announced that Chief Financial Officer Thomas Burns is stepping down to pursue other opportunities, after nearly two decades of service. CEO Owen Hughes praised Burns' leadership and dedication, noting the strong financial foundation he built. Burns expressed pride in XOMA Royalty's journey and its established position in the biotech royalty sector. Jeffrey Trigilio has been appointed as the new CFO, bringing extensive ex...
01-12 12:30
Takeda, XOMA ink new royalty agreement; amend existing deal
XOMA Royalty Corporation (XOMA) on Tuesday announced that it reached a new royalty sharing transaction with Takeda (TAK) and amended its existing royalty sharing agreement for the Japanese drugmaker’s...
2025-12-30 21:14
XOMA Royalty Amends Its Collaboration, Originally Established In 2006, With Takeda Through Strategic Royalty Share Transaction
Takeda's royalty and milestone payment obligations to XOMA Royalty related to mezagitamab will be reducedXOMA Royalty will receive payments based on low to mid-single-digit royalties and milestones across a basket of
2025-12-30 20:38
XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab
XOMA Royalty Corporation and Takeda have amended their 2006 collaboration, reducing Takeda’s royalty and milestone payments for mezagitamab while granting XOMA Royalty payments tied to nine development-stage assets in Takeda’s externalized portfolio. This move diversifies XOMA’s portfolio across early- and late-stage programs, balancing risk and opportunity.
2025-12-30 12:30
XOMA Preferred Shares Series A declares $0.5391 dividend
XOMA Preferred Shares Series A (XOMAP) declares $0.5391/share quarterly dividend. Forward yield 8.08% Payable Jan. 15; for shareholders of record Jan. 2; ex-div Jan. 2. See XOMAP Dividend Scorecard, Y...
2025-12-23 04:57
XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend
XOMA Corp - 8.375% DP PFD B (XOMAO) declares $0.5234/share quarterly dividend. Forward yield 8.2% Payable Jan. 15; for shareholders of record Jan. 2; ex-div Jan. 2. See XOMAO Dividend Scorecard, Yield...
2025-12-23 04:56
XOMA Royalty Declares Quarterly Preferred Stock Dividends
XOMA Royalty Corporation的董事会已授权向Series A和Series B优先股持有者发放现金股息，金额分别为每股$0.53906和每存款凭证$0.52344，支付日期为2026年1月15日，记录日为2026年1月2日。该公司是生物技术专利权聚合商，专注于收购与治疗药物相关的未来经济权益，支持生物技术公司提升人类健康。其资产组合包括已商业化的药物如VABYSMO和DSUVIA等，以及其他处于开发阶段的药物，这些药物的疗效和安全性尚未确定，未来能否商业化尚有风险。
2025-12-22 12:30
